ArticleOncotarget2017

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.

Juliann E Kosovec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.